» Articles » PMID: 9920284

Internalisation of the Bleomycin Molecules Responsible for Bleomycin Toxicity: a Receptor-mediated Endocytosis Mechanism

Overview
Date 1999 Jan 27
PMID 9920284
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

Bleomycin (BLM) does not diffuse through the plasma membrane but nevertheless displays cytotoxic activity due to DNA break generation. The aim of the study was to describe the mechanism of BLM internalisation. We previously provided evidence for the existence of BLM-binding sites at the surface of DC-3F Chinese hamster fibroblasts, as well as of their involvement in BLM cytotoxicity on DC-3F cells and related BLM-resistant sublines. Here we report that A253 human cells and their BLM-resistant subline C-10E also possessed a membrane protein of ca. 250 kDa specifically binding BLM. Part of this C-10E cell resistance could be explained by a decrease in the number of BLM-binding sites exposed at the cell surface with respect to A253 cells. The comparison between A253 and DC-3F cells exposing a similar number of BLM-binding sites revealed that the faster the fluid phase endocytosis, the greater the cell sensitivity to BLM. Moreover, the experimental modification of endocytotic vesicle size showed that BLM cytotoxicity was directly correlated with the flux of plasma membrane area engulfed during endocytosis rather than with the fluid phase volume incorporated. Thus, BLM would be internalised by a receptor-mediated endocytosis mechanism which would first require BLM binding to its membrane receptor and then the transfer of the complex into intracellular endocytotic vesicles, followed by BLM entry into the cytosol, probably from a nonacidic compartment.

Citing Articles

Canine lung carcinoma-A descriptive review.

Marcinowska A, Horta R, Queiroga F, Giuliano A Front Vet Sci. 2025; 11:1464659.

PMID: 39902337 PMC: 11788302. DOI: 10.3389/fvets.2024.1464659.


Enhancing the Efficacy of Radiation Therapy by Photochemical Internalization of Fibrin-Hydrogel-Delivered Bleomycin.

Laurel S, Gupta K, Nguyen J, Chandekar A, Le J, Berg K Cancers (Basel). 2024; 16(23).

PMID: 39682215 PMC: 11640518. DOI: 10.3390/cancers16234029.


Photochemical Internalization with Fimaporfin: Enhanced Bleomycin Treatment for Head and Neck Cancer.

Enzian P, Rahmanzadeh R Pharmaceutics. 2023; 15(8).

PMID: 37631254 PMC: 10458762. DOI: 10.3390/pharmaceutics15082040.


Retrospective Evaluation of a Combination of Carboplatin and Bleomycin for the Treatment of Canine Carcinomas.

Giuliano A, Almendros A Animals (Basel). 2022; 12(18).

PMID: 36139200 PMC: 9495018. DOI: 10.3390/ani12182340.


Effective Penetration of a Liposomal Formulation of Bleomycin through Ex-Vivo Skin Explants from Two Different Species.

Ferrari G, Pang L, de Moliner F, Vendrell M, Reardon R, Higgins A Cancers (Basel). 2022; 14(4).

PMID: 35205831 PMC: 8870439. DOI: 10.3390/cancers14041083.